DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic Cancer

Early Phase 1

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: [18F]FluorThanatrace ([18F]FTT)

First Posted Date: 2018-04-10

Last Posted Date: 2024-06-12

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 6

Registration Number: NCT03492164

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Avelumab/Gemcitabine in Sarcomatoid RCC

Phase 1

Terminated

Conditions: Metastatic sRCC

Interventions: Drug: Avelumab
Drug: Gemcitabine

First Posted Date: 2018-03-30

Last Posted Date: 2022-08-26

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 6

Registration Number: NCT03483883

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Personalized Radiation Therapy for GBM

Not Applicable

Active, not recruiting

Conditions: Glioblastoma

Interventions: Radiation: Radation Therapy

First Posted Date: 2018-03-26

Last Posted Date: 2024-06-07

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 20

Registration Number: NCT03477513

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Randomized Study to Establish the Efficacy of Oral Ice Exposure During Oxaliplatin Infusion in Preventing Oral Cold Sensitivity

Early Phase 1

Terminated

Conditions: GI Patients on Oxaliplatin Containing Regimen

Interventions: Drug: Oxaliplatin

First Posted Date: 2018-02-09

Last Posted Date: 2020-04-08

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 65

Registration Number: NCT03427021

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")

Phase 1

Withdrawn

Conditions: Breast Cancer

Interventions: Drug: Hydroxychloroquine (HCQ)
Drug: Gedatolisib

First Posted Date: 2018-01-17

Last Posted Date: 2020-04-28

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Registration Number: NCT03400254

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

AYA STEPS RCT: AYA Self-Management Via Texting, Education & Plans for Survivors

Active, not recruiting

Conditions: Adolescent and Young Adult (AYA) Cancer Survivors

First Posted Date: 2017-12-06

Last Posted Date: 2025-01-06

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 25

Registration Number: NCT03363711

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer

Early Phase 1

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Device: [18F]FluorThanatrace
Drug: Poly(ADP Ribose) Polymerase 1

First Posted Date: 2017-11-07

Last Posted Date: 2024-08-27

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 30

Registration Number: NCT03334500

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer

Phase 1

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: Paricalcitol

First Posted Date: 2017-10-04

Last Posted Date: 2022-03-31

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 3

Registration Number: NCT03300921

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: hydroxychloroquine
Drug: entinostat
Drug: regorafenib

First Posted Date: 2017-07-12

Last Posted Date: 2023-11-09

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 20

Registration Number: NCT03215264

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma

Early Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Blinatumomab

First Posted Date: 2017-06-01

Last Posted Date: 2020-02-07

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 6

Registration Number: NCT03173430

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy